Essentially, what it looks like regulators(MHRA) and NWBO are considering has been to establish an environment where rGBM and nGBM can be commercialized whilst DCVax-l and DCVax-Direct can be used in specials for all solid tumor cancers and collect real world evidence, without interfering with DCVax-L’s commercial profitability intellectual property through orphan designated exclusive use IP DCVax-l using for GBM. For L, once enough data collected they would probably only commercialize more orphan diseases, like pancreatic or recurrent ovarian platinum resistant, for example, and piggy back on the exclusive use, however, for DCVax-Direct, which has a robust patent out to 2036, they could commercialize whatever worked in specials and/or trials. Finally, combos likely only initially in trials.
Market Data 
Markets 
AI
